Literature DB >> 16540640

Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.

Crissy Dudgeon1, Calvina Kek, Oleg N Demidov, Shin-ichi Saito, Kenneth Fernandes, Alexandra Diot, Jean-Christophe Bourdon, David P Lane, Ettore Appella, Albert J Fornace, Dmitry V Bulavin.   

Abstract

Activation of apoptosis is believed to be critical for the role of p53 as a tumor suppressor. Here, we report a new mouse strain carrying a human p53 transgene in the mouse p53-null background. Expression of human p53 in these mice was comparable with wild-type murine p53; however, transactivation, induction of apoptosis, and G(1)-S checkpoint, but not transrepression or regulation of a centrosomal checkpoint, were deregulated. Although multiple functions of p53 were abrogated, mice carrying the human p53 transgene did not show early onset of tumors as typically seen for p53-null mice. In contrast, human p53 in the p53-null background did not prevent accelerated tumor development after genotoxic or oncogenic stress. Such behavior of human p53 expressed at physiologic levels in transgenic cells could be explained by unexpectedly high binding with Mdm2. By using Nutlin-3a, an inhibitor of the interaction between Mdm2 and p53, we were able to partially reconstitute p53 transactivation and apoptosis in transgenic cells. Our findings indicate that the interaction between p53 and Mdm2 controls p53 transcriptional activity in homeostatic tissues and regulates DNA damage- and oncogene-induced, but not spontaneous, tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540640     DOI: 10.1158/0008-5472.CAN-05-2063

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Authors:  Yintao Ye; Wenqing Xu; Wei Zhong; Yajing Li; Chen Wang
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

2.  Mouse models for the p53 R72P polymorphism mimic human phenotypes.

Authors:  Feng Zhu; Martijn E T Dollé; Thomas R Berton; Raoul V Kuiper; Carrie Capps; Alexsandra Espejo; Mark J McArthur; Mark T Bedford; Harry van Steeg; Annemieke de Vries; David G Johnson
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

Review 3.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

4.  Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.

Authors:  Vera V Grinkevich; Aparna Vema; Karin Fawkner; Natalia Issaeva; Virginia Andreotti; Eleanor R Dickinson; Elisabeth Hedström; Clemens Spinnler; Alberto Inga; Lars-Gunnar Larsson; Anders Karlén; Margareta Wilhelm; Perdita E Barran; Andrei L Okorokov; Galina Selivanova; Joanna E Zawacka-Pankau
Journal:  Front Mol Biosci       Date:  2022-06-01

Review 5.  How to become immortal: let MEFs count the ways.

Authors:  Adam Odell; Jon Askham; Catherine Whibley; Monica Hollstein
Journal:  Aging (Albany NY)       Date:  2010-03-31       Impact factor: 5.682

6.  Regulation of apoptosis by Caspases under oxidative stress conditions in mice testicular cells: in vitro molecular mechanism.

Authors:  Sumiti Kalia; M P Bansal
Journal:  Mol Cell Biochem       Date:  2008-11-01       Impact factor: 3.396

Review 7.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.